Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18328259 | 1.00 | PTPN11 (0.32) | PTPN11 | |
| SCHEMBL24703609 | 1.00 | PTPN11 (0.32) | PTPN11 | |
| Hydrochloric Acid SCHEMBL21952191 | 0.98 | PTPN11 (0.31) | PTPN11 | |
| Hydrochloric Acid SCHEMBL21952176 | 0.98 | PTPN11 (0.31) | PTPN11 | |
| Hydrochloric Acid SCHEMBL30556616 | 0.98 | PTPN11 (0.31) | PTPN11 | |
| Hydrochloric Acid SCHEMBL21952192 | 0.98 | PTPN11 (0.31) | PTPN11 | |
| Trifluoroacetic Acid SCHEMBL30556602 | 0.83 | PTPN11 (0.31) | PTPN11 | |
| SCHEMBL14108539 | 0.74 | — | — | |
| SCHEMBL13931091 | 0.74 | — | — | |
| SCHEMBL22050053 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250082648-A1 | COMPOSITIONS AND METHODS FOR ENHANCING KRAS INHIBITOR OR SHP2 INHIBITOR EFFICACY | NEW YORK UNIVERSITY (US) | 2025-03-13 | — | — | US | claimed |
| CN-114341124-B | Protein tyrosine phosphatase inhibitors | ARRAY生物制药公司 | 2024-09-20 | — | — | CN | claimed |
| US-20230285498-A1 | TREATMENTS FOR CANCERS HAVING KRAS MUTATIONS | CITY OF HOPE | 2023-09-14 | — | — | US | claimed |
| CN-116724042-A | Heterotricyclic compound and preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2023-09-08 | — | — | CN | claimed |
| CN-110730678-B | Pharmaceutical combination comprising an ALK inhibitor and an SHP2 inhibitor | 诺华股份有限公司 | 2022-07-15 | — | — | CN | claimed |
| WO-2022031952-A9 | TREATMENTS FOR CANCERS HAVING KRAS MUTATIONS | CITY OF HOPE (US) | 2022-04-07 | — | — | WO | claimed |
| WO-2022031952-A2 | TREATMENTS FOR CANCERS HAVING KRAS MUTATIONS | CITY OF HOPE (US) | 2022-02-10 | — | — | WO | claimed |
| EP-3568204-A1 | PHARMACEUTICAL COMBINATION COMPRISING AN ALK INHIBITOR AND A SHP2 INHIBITOR | Novartis AG (CH) | 2019-11-20 | — | — | EP | claimed |
| WO-2018130928-A1 | PHARMACEUTICAL COMBINATION COMPRISING AN ALK INHIBITOR AND A SHP2 INHIBITOR | NOVARTIS AG (CH) | 2018-07-19 | — | — | WO | claimed |
| US-20260102394-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2026-04-16 | — | — | US | disclosed |
| US-12458640-B2 | Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-11-04 | — | — | US | disclosed |
| EP-4598916-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250082648-A1 | COMPOSITIONS AND METHODS FOR ENHANCING KRAS INHIBITOR OR SHP2 INHIBITOR EFFICACY | NEW YORK UNIVERSITY (US) | 2025-03-13 | — | — | US | disclosed |
| CN-113880842-B | Substituted alkynyl heterocyclic compounds | 首药控股(北京)股份有限公司 | 2025-02-25 | — | — | CN | disclosed |
| EP-3724189-A1 | POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. (US) | 2020-10-21 | — | — | EP | disclosed |
| EP-3468972-B1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2020-05-20 | — | — | EP | disclosed |
| WO-2020022323-A1 | HETEROBICYCLIC COMPOUNDS FOR INHIBITING THE ACTIVITY OF SHP2 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-01-30 | — | — | WO | disclosed |
| WO-2019118909-A1 | POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. (US) | 2019-06-20 | — | — | WO | disclosed |
| US-20190185475-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2019-06-20 | — | — | US | disclosed |
| EP-3310779-B1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2019-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12458640-B2 | Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors | PTPN5, PTPRZ1, PTPN1 | PTPN11 6/4885 |
| US-20190185475-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | PTPN1, PTPN3, PTPN5 | PTPN11 12/4885 |
| US-20260102394-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS | PTPN5, PTPN1, PTPN3 | PTPN11 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.